Immunotherapy in the First-Line Setting in Wild-Type NSCLC

by Marie-Hélène Denault, Barbara Melosky
Published 2021-11-01

Wait Times and Survival in Lung Cancer Patients across the Province of Quebec, Canada

by Marie-Hélène Denault, Catherine Labbé, Carolle St-Pierre, Brigitte Fournier, Andréanne Gagné, Claudia Morillon, Philippe Joubert, Serge Simard, Simon Martel
Published 2022-04-01

Beyond PACIFIC: Real-World Outcomes of Adjuvant Durvalumab According to Treatment Received and PD-L1 Expression

by Marie-Hélène Denault, Jamie Feng, Shelley Kuang, Aria Shokoohi, Bonnie Leung, Mitchell Liu, Eric Berthelet, Janessa Laskin, Sophie Sun, Tina Zhang, Cheryl Ho, Barbara Melosky
Published 2023-08-01

Comparison of 2-Weekly Versus 4-Weekly Durvalumab Consolidation for Locally Advanced NSCLC Treated With Chemoradiotherapy: A Brief Report

by Marie-Hélène Denault, MD, MSc, Shelley Kuang, MD, FRCPC, Aria Shokoohi, BSc, Bonnie Leung, MN-NP, Mitchell Liu, MDCM, FRCPC, Eric Berthelet, MD, FRCPC, Janessa Laskin, MD, FRCPC, Sophie Sun, MD, FRCPC, Tina Zhang, MD, FRCPC, Barbara Melosky, MD, FRCPC, Cheryl Ho, MD, FRCPC
Published 2022-05-01